Compositions for regenerating defective or absent myocardium
First Claim
1. An injectable graft composition for myocardial tissue regeneration, said composition comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular small intestine submucosa, said ECM comprising native proteoglycans, transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added supplemental bioactive component comprising a vascular endothelial growth factor (VEGF), said VEGF comprising greater than 0.1% by weight of said composition,said VEGF component being linked to a molecule in the ECM, wherein said VEGF component interacts with said proteoglycans to control matrix formation and remodeling, wherein, when said ECM composition is administered to damaged or diseased cardiovascular tissue, said ECM composition induces stem cell proliferation, differentiation of stem cells into cardiomyocytes and, thereby, angiogenesis.
3 Assignments
0 Petitions
Accused Products
Abstract
Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
6 Citations
1 Claim
-
1. An injectable graft composition for myocardial tissue regeneration, said composition comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular small intestine submucosa, said ECM comprising native proteoglycans, transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added supplemental bioactive component comprising a vascular endothelial growth factor (VEGF), said VEGF comprising greater than 0.1% by weight of said composition,
said VEGF component being linked to a molecule in the ECM, wherein said VEGF component interacts with said proteoglycans to control matrix formation and remodeling, wherein, when said ECM composition is administered to damaged or diseased cardiovascular tissue, said ECM composition induces stem cell proliferation, differentiation of stem cells into cardiomyocytes and, thereby, angiogenesis.
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added supplemental bioactive component comprising a vascular endothelial growth factor (VEGF), said VEGF comprising greater than 0.1% by weight of said composition,
Specification